David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.04% |
| 2 | Healthcare | 13.44% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Financials | 7.19% |
| 5 | Industrials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3276
Fox Class B
FOX
$26.4B
| $240K | ﹤0.01% |
+6,688
| New | +$255K |
|
3277
Hamilton Beach Brands
HBB
$438M
| $240K | ﹤0.01% |
11,171
+8
| +0.1% | +$194 |
|
3278
Nokia
NOK
$57.8B
| $239K | ﹤0.01% |
41,843
-10,621,606
| -100% | -$65M |
|
3279
Viridian Therapeutics
VRDN
$2.74B
| $239K | ﹤0.01% |
5,710
+1,770
| +45% | +$80.1K |
|
3280
Verastem
VSTM
$641M
| $239K | ﹤0.01% |
6,721
-38,272
| -85% | -$1.51M |
|
3281
CALL
Corning
GLW
$127B
| $238K | ﹤0.01% |
+7,200
| New | +$236K |
|
|
SUP
3282
PUT
DELISTED
Superior Industries International
SUP
| $238K | ﹤0.01% |
50,000
| – | – |
|
3283
Power Integrations
POWI
$3.05B
| $237K | ﹤0.01% |
6,788
-3,190
| -32% | -$108K |
|
|
RDS.B
3284
CALL
DELISTED
Royal Dutch Shell PLC ADS Class B
RDS.B
| $237K | ﹤0.01% |
+3,700
| New | +$234K |
|
|
SINA
3285
CALL
DELISTED
Sina Corp
SINA
| $237K | ﹤0.01% |
4,000
-6,000
| -60% | -$360K |
|
|
NLSN
3286
PUT
DELISTED
Nielsen Holdings plc
NLSN
| $237K | ﹤0.01% |
+10,000
| New | +$259K |
|
|
TOUR
3287
Tuniu
TOUR
$52.6M
| $236K | ﹤0.01% |
4,923
-254
| -5% | -$12.4K |
|
|
AIG.WS
3288
DELISTED
American International Group, Inc.
AIG.WS
| $236K | ﹤0.01% |
41,284
| – | – |
|
3289
PUT
Intuit
INTU
$97.8B
| $235K | ﹤0.01% |
+900
| New | +$208K |
|
3290
CRISPR Therapeutics
CRSP
$5.89B
| $234K | ﹤0.01% |
6,552
-18,160
| -73% | -$628K |
|
3291
Rigel Pharmaceuticals
RIGL
$873M
| $234K | ﹤0.01% |
9,103
-2,228
| -20% | -$50.9K |
|
3292
PUT
SM Energy
SM
$8.49B
| $234K | ﹤0.01% |
+13,400
| New | +$238K |
|
3293
Descartes Systems
DSGX
$6.64B
| $233K | ﹤0.01% |
6,400
-19,600
| -75% | -$634K |
|
3294
CALL
MKS Inc
MKSI
$18.3B
| $233K | ﹤0.01% |
+2,500
| New | +$202K |
|
|
SCWX
3295
DELISTED
SecureWorks Corp Class A Common Stock
SCWX
| $232K | ﹤0.01% |
12,606
+600
| +5% | +$11.7K |
|
3296
Cars.com
CARS
$661M
| $231K | ﹤0.01% |
+10,147
| New | +$245K |
|
3297
Provident Financial Services
PFS
$3.06B
| $231K | ﹤0.01% |
8,939
-4,307
| -33% | -$113K |
|
3298
Brighthouse Financial
BHF
$2.98B
| $228K | ﹤0.01% |
6,290
-9,262
| -60% | -$347K |
|
3299
Liberty Latin America Class C
LILAK
$1.67B
| $228K | ﹤0.01% |
13,691
| – | – |
|
3300
Artivion
AORT
$1.29B
| $227K | ﹤0.01% |
7,779
-1,875
| -19% | -$53.5K |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $6.74B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.